Clinical Trials

Metastatic Castrate Resistant Prostate Cancer

KLK2 – PASenger – Janssen

• A study for men with metastatic prostate cancer that is castrate resistant and have progressed on current therapy
• This study aims to determine whether treatment with pasritamig + docetaxel prolongs progression free survival compared with docetaxel alone
• PASenger patient brochure

Click Here to Learn More

 

LEGION-100 – Syncromune

• A study for men with metastatic prostate cancer with progression on current therapy.
• This study aims to evaluate the safety and tolerability of SYNC-T Therapy SV-102.
  • Study treatment will be a combination therapy consisting of a cryoablation followed by the intratumoral infusion of SV-102.

Click Here to Learn More

 

MEVPRO-2 – Pfizer

• A study for men with metastatic prostate cancer that is castrate resistant and not yet received chemotherapy or novel hormonal therapy
• This study aims to demonstrate that mevrometastat in combination with enzalutamide is superior to placebo in combination with enzalutamide in prolonging progression free survival
• What is MEVPRO-2, MEVPRO-2 Patient Brochure

Click Here to Learn More

 

Imaging Trials

Solar-Stage – Curium

• An imaging study for men with newly diagnosed high-risk or very high-risk prostate cancer that are electing to undergo radical prostatectomy
• To determine the diagnostic performance of copper Cu 64 PSMA I&T PET/CT for the detection of presence or absence of pelvic lymph node metastasis in pre-prostatectomy patients
• Solar-Stage Patient Brochure

Click Here to Learn More

 

 

Intermediate Risk – Non-Muscle Invasive Bladder Cancer

ABLE-32 – Ferring

• New or recurrent Intermediate risk NMIBC patients
• Treatment (Adstiladrin) vs Observation – there is an opportunity for those who recur on observation to cross over to the treatment group.
  • Adstiladrin is currently FDA approved for recurrent high-risk patients that have failed BCG therapy.
  • About Adstiladrin
  • Able-32 Patient Brochure

Click Here to Learn More

 

LEGEND – EnGene

• Patients with intermediate risk bladder cancer
• Medication: EG-70 – a non-viral gene therapy administered into the bladder. Polidocanol (bladder rinse) to help the EG-70 work more effectively within the bladder
• brochures coming soon

Click Here to Learn More

 

RESCUE – cohort 1 – Relmada

• New or recurrent Intermediate risk NMIBC patients (excludes LgT1 tumors)
• Medication: NDV-01 – a gemcitabine/docetaxel formulation that forms a soft, spherical matrix in the bladder that gradually dissolves over 10 days
  • good for those who cannot hold their bladder for typical bladder instillations.

Click Here to Learn More

 

SURF-302 – TYRA

• New or recurrent Intermediate risk NMIBC patients with the FGFR3 mutation
  • we test for FGFR3 before biopsy to determine if the patient has the mutation
• Medication: Dabogratinib – Pill taken once daily to eliminate current bladder tumors.
  • The goal is to have an approval oral medication for patients to reduce the number of transurethral resections needed
• SURF-302 Patient Brochure

Click Here to Learn More

 

High-Risk – Non-Muscle Invasive Bladder Cancer

ABLE-22

• Patients with carcinoma in-situ (CIS) who have previously been treated with BCG and recurred.
• 3 groups that patients will be divided into
  • group 1: Adstiladrin
  • group 2: Adstiladrin + gemcitabine/docetaxel
  • group 3: Adstiladrin + Keytruda
• ABLE-22 Patient Brochure

Click Here to Learn More

 

ADVANCED-2 – ProTara

• Patients with carcinoma in-situ (CIS) that are BCG unresponsive
• Medication: TARA-002 – a biological preparation containing cells of Streptococcus pyogenes that creates an immune response to tumor cells.
• Advanced-2 Flyer

Click Here to Learn More

 

LAUREL – SURGE – STM-416

• Patients that have been previously diagnosed with high grade bladder cancer and have a recurrence on cystoscopy
• Medication: STM-416 – immunotherapy injected into the bladder wall during resection.
• LAUREL Brochure

Click Here to Learn More

 

LEGEND – EnGene

• Patients with carcinoma in-situ (CIS) that are BCG unresponsive
• Medication: EG-70 – a non-viral gene therapy administered into the bladder. Polidocanol (bladder rinse) to help the EG-70 work more effectively within the bladder
• Legend – bladder rinse sub study brochure

Click Here to Learn More

 

RESCUE – cohort 2 – Relmada

• Patients with high-risk bladder cancer that have tried BCG in the past and recurred
• Medication: NDV-01 – a gemcitabine/docetaxel formulation that forms a soft, spherical matrix in the bladder that gradually dissolves over 10 days
  • good for those who cannot hold their bladder for typical bladder instillations.

Click Here to Learn More

Muscle Invasive Bladder Cancer

7465-CL-0209 – Astellas

• Patients that are newly diagnosed with muscle invasive bladder cancer and would like to try a bladder sparing approach without chemotherapy.
• Medications: Enfortumab Vendotin + Keytruda – immunotherapy infusions

Click Here to Learn More

TELIX

An Expanded Access Program for the non-invasive detection of clear cell renal cell carcinoma (ccRCC) in patients with renal masses utilizing 89Zirconium-labelled girentuximab (89Zr-DFO-girentuximab)

Click Here to View a Video About Telix

Click Here for the Patient Brochure

Benign Prostatic Hyperplasia

PEAK – Urotronic

• Men 50 years or older that have been diagnosed with BPH and are willing to participate in a semen analysis sub-study.
• Intervention: Optilume drug-coated balloon – Click here to see a video about the treatment

 

Urge Urinary Incontinence

eCoin – Valencia Technologies

• eCoin® is the first FDA-approved tibial stimulator device for Urge Urinary Incontinence (UUI). The coin-sized device is placed under the skin, near the ankle during a safe and minimally invasive procedure.

Click Here to Review  the eCoin Info and View Video